Oral semaglutide vs orforglipron: what ORION’s indirect comparison tells clinicians and patients now
The ORION analysis from Novo Nordisk used population-adjusted indirect comparison methods to contrast oral semaglutide 25 mg tablets with Eli…
OTOF gene therapy restored hearing after one inner‑ear injection in a 10‑patient trial — who it helps and what comes next
A single inner‑ear injection of AAV‑mediated gene therapy that replaces the defective OTOF gene restored measurable hearing in all ten…
CK1 inhibitors protect human cone photoreceptors in a 2,700‑compound organoid screen — safety and delivery are the next hurdles
A large-scale screen using 20,000 human retinal organoids with GFP-labeled cones found that inhibiting casein kinase 1 (CK1) consistently protected…
DFNZ: NIH’s nitazene‑derived opioid produced two‑hour pain relief in rodents without respiratory depression
NIH scientists report a novel opioid, DFNZ, that in rodents produced sustained pain relief for over two hours while, unusually…
Whole-genome sequencing finds a reproducible microbial fingerprint unique to colorectal cancer
Whole‑genome sequencing (WGS) of more than 9,000 cancer patients has revealed that colorectal tumors—alone among common tumor types—consistently host a…
Solriamfetol delivers measurable wakefulness gains for early‑morning shift workers with shift work disorder
Clinical trial data show solriamfetol can modestly but reliably increase wakefulness in people with shift work disorder who start work…
Efzimfotase alfa: clear pediatric bone‑health benefit; adult gains concentrated in pediatric‑onset HPP
Efzimfotase alfa, a next‑generation enzyme replacement therapy from AstraZeneca Rare Disease, produced a clear, statistically significant bone‑health signal in treatment‑naïve…
Salt substitutes cut blood pressure — who should try them, who should not, and how to decide
Salt substitutes — typically sodium chloride partially replaced by potassium chloride — are an inexpensive, evidence-backed way to lower blood…